(Health-NewsWire.Net, June 20, 2017 ) Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts) . Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 16, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/gastrointestinal-stromal-tumor-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology) . - The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834409/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
AB Science SA Advanced Accelerator Applications SA Advenchen Laboratories LLC Ariad Pharmaceuticals Inc Arog Pharmaceuticals Inc ArQule Inc Array BioPharma Inc Astex Pharmaceuticals Inc Blueprint Medicines Corp Boston Biomedical Inc Calithera Biosciences Inc Celldex Therapeutics Inc Chipscreen Biosciences Ltd CytRx Corp Deciphera Pharmaceuticals LLC Exelixis Inc F. Hoffmann-La Roche Ltd Hanmi Pharmaceuticals Co Ltd Horizon Pharma Plc Immunicum AB Jiangsu Hengrui Medicine Co Ltd Natco Pharma Ltd Nerviano Medical Sciences Srl Novartis AG Omeros Corp Pharma Mar SA Plexxikon Inc Rhizen Pharmaceuticals SA Taiho Pharmaceutical Co Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834409/discount
Table of Contents
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) , H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications SA, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories LLC, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by CytRx Corp, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2017 Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834409/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|